超声诊断子宫内膜异位症和/或子宫腺肌症女性连续三个IVF/ICSI治疗周期的累积活产率降低
前瞻性队列研究纳入1035例接受最多三个连续IVF/ICSI周期的女性,采用IDEA和修订MUSA超声定义诊断子宫内膜异位症和/或子宫腺肌症。293例(28.3%)患病女性三个周期累积活产率在ITT分析为53.2%、PP分析为70.0%,均低于无病女性的68.7%和85.7%,校正后aRR分别为0.80和0.85。
要点
- 超声诊断子宫内膜异位症和/或子宫腺肌症者三个周期累积活产率显著低于无病女性。
- ITT分析aRR 0.80(95%CI 0.71-0.90),PP分析aRR 0.85(95%CI 0.77-0.93)。
- 首个治疗周期差异最大,aRR 0.69(95%CI 0.57-0.84);第三个周期aRR 0.83(95%CI 0.54-1.28)未达统计学显著。
核心结论
- 经阴道超声诊断子宫内膜异位症和/或子宫腺肌症的女性连续三个IVF/ICSI周期累积活产几率较无病女性降低15%。
- 尽管累积活产率较低,患病女性连续治疗仍有合理活产机会,首次治疗失败不应作为停止进一步尝试的理由。
研究设计与样本
- 前瞻性队列研究,2019年1月至2024年4月在一所大学医院纳入1035例接受最多三个连续IVF/ICSI治疗的女性。
- 所有女性在首次治疗前接受经阴道超声检查,依据IDEA和修订MUSA定义诊断。
- 293例(28.3%)女性超声提示子宫内膜异位症和/或子宫腺肌症直接特征;818例(79.0%)完成了符合资格的全部治疗。
主要发现
- 全队列三个连续周期累积活产率为666/818(81.4%)。
- ITT分析:患病女性累积活产156/293(53.2%)vs 无病女性510/742(68.7%),P < 0.001。
- PP分析:患病女性累积活产156/223(70.0%)vs 无病女性510/595(85.7%),P < 0.001。
- 校正年龄后aRR(ITT)0.80(95%CI 0.71-0.90),P < 0.001;aRR(PP)0.85(95%CI 0.77-0.93),P < 0.001。
- 分层分析:第一周期活产率患病组90/293(30.7%)vs 无病组335/742(45.1%),aRR 0.69(95%CI 0.57-0.84),P < 0.001;第二周期44/154(28.6%)vs 132/319(41.4%),aRR 0.72(95%CI 0.54-0.96),P = 0.023;第三周期22/84(26.2%)vs 43/133(32.3%),aRR 0.83(95%CI 0.54-1.28),P = 0.183。
临床怎么用
- 作者认为,尽管三个IVF/ICSI周期累积活产率较低,患病女性连续治疗仍有合理活产机会,首次治疗阴性结果不应作为停止进一步尝试的理由。
- 作者提出未来研究应探索提高该人群治疗成功率的策略,包括长期抑制方案、外源性孕酮给药和个体化胚胎移植方法的作用。
局限性
- 超声检查由一位在子宫内膜异位症和子宫腺肌症方面有专长的检查者在一所三级医院完成。
- 根据修订MUSA定义,子宫腺肌症直接特征为病理特异性,而间接特征仅提示疾病;仅具间接特征者在本研究中被视为健康,可能被错误分类。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does endometriosis and/or adenomyosis, diagnosed using the International Deep Endometriosis Analysis (IDEA) group and the Morphological Uterus Sonographic Assessment (MUSA) group revised definitions, impact cumulative live birth rates (CLBR) after three consecutive IVF or ICSI treatments? SUMMARY ANSWER: Women with endometriosis and/or adenomyosis, as diagnosed using transvaginal ultrasonography, had a 15% reduced chance of having a cumulative live birth after three consecutive IVF/ICSI treatments compared to women without these conditions. WHAT IS KNOWN ALREADY: Women with endometriosis or adenomyosis reportedly have lower live birth rates after their first IVF/ICSI treatment. However, most women undergo multiple cycles, and given their shared pathophysiology, the combined impact of both conditions over consecutive treatments remains unclear. STUDY DESIGN, SIZE, DURATION: This was a prospective cohort study of 1035 women undergoing up to three consecutive IVF/ICSI treatments at a university hospital between January 2019 and April 2024. Swedish regulations entitle women to up to three subsidized treatment cycles, including fresh and/or frozen embryo transfers, until the birth of a living child is achieved. PARTICIPANTS/MATERIALS, SETTING, METHODS: All 1035 included women underwent a transvaginal ultrasound examination prior to starting their first treatment. Using the IDEA and revised MUSA definitions, respectively, in total 293 (28.3%) women had endometriosis and/or direct features of adenomyosis on ultrasonography. All 1035 women underwent the first treatment cycle. In total, 818 (79.0%) women [595 (80.2%) of women without endometriosis and/or adenomyosis and 223 (76.1%) of women with either of the diseases] underwent all treatments they were eligible for. A total of 217 (21.0%) women dropped out after the first or second treatment even if they had not achieved a live birth. In total, 1725 fresh treatment cycles were initiated, leading to 1283 fresh and 622 frozen embryo transfers. Live births were recorded. The adjusted relative risk (aRR) for cumulative live birth after three consecutive IVF/ICSI treatment cycles was calculated on an intention-to-treat (ITT) as well as per-protocol (PP) basis, using a modified Poisson regression analysis, adjusting for age as a potential confounder. MAIN RESULTS AND THE ROLE OF CHANCE: The CLBR over three consecutive IVF/ICSI treatment cycles was 666/818 (81.4%) in the total cohort. In an ITT and PP analyses, respectively, women with endometriosis and/or adenomyosis had a lower CLBR of 156/293 (53.2%) or 156/223 (70.0%) compared to women without, CLBR of 510/742 (68.7%) or 510/595 (85.7%), P < 0.001. The aRR for cumulative live birth for women with endometriosis and/or adenomyosis was aRR (ITT) 0.80 (95% CI, 0.71-0.90), P < 0.001, and aRR (PP) 0.85 (95% CI, 0.77-0.93), P < 0.001 compared to women without the diseases. After stratifying the results per treatment cycle, the LBR after the first treatment for women with endometriosis and/or adenomyosis was 90/293 (30.7%), aRR 0.69 (95% CI 0.57-0.84), P < 0.001, after the second 44/154 (28.6%), aRR 0.72 (95% CI 0.54-0.96), P = 0.023, and after the third treatment 22/84 (26.2%), aRR 0.83 (95% CI 0.54-1.28), P = 0.183. For women without the diseases, the LBR was 335/742 (45.1%) in the first cycle, 132/319 (41.4%) in the second, and 43/133 (32.3%) in the third cycle. The largest differences were seen after fresh compared to frozen embryo transfers. LIMITATIONS, REASONS FOR CAUTION: The ultrasound examinations were performed at a tertiary care hospital by an examiner with expertise in endometriosis and adenomyosis. According to the revised MUSA definitions, direct features of adenomyosis are pathognomonic, whereas indirect features are only indicative of the disease. It is possible that some women with only indirect features, who were considered healthy in this study, in fact had the disease and therefore were wrongly classified. WIDER IMPLICATIONS OF THE FINDINGS: Despite a lower CLBR over three IVF/ICSI cycles, women with endometriosis and/or adenomyosis still have a reasonable chance of achieving a live birth with consecutive treatments. Negative results after the first treatment should not be an argument to withhold further attempts. Future research should explore strategies to enhance treatment success in this population, including the role of long-term suppression protocols, exogenous progesterone dosing, and personalized embryo transfer approaches. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by regional research grants from Region Skåne, Sweden. TRIAL REGISTRATION NUMBER: N/A.
引用
- Alson S, Stenqvist A, Sladkevicius P, et al. Cumulative live birth rates under three consecutive IVF/ICSI treatment cycles are reduced in women with endometriosis and/or adenomyosis diagnosed by ultrasonography. Hum Reprod. 2025. PMID: 40974212. doi:10.1093/humrep/deaf184
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。